. Author manuscript; available in PMC: 2012 Oct 15.

Published in final edited form as: Clin Breast Cancer. 2010;10(Suppl 1):E23–E31. doi: 10.3816/CBC.2010.s.004

Table 2.

Results From Phase II Trials of Bevacizumab in the Neoadjuvant Setting

Study	Phase	IHC Status	Neoadjuvant Treatment	N	cCR,^a %	pCR,^b %
Balduzzi et al⁶⁶	II	HER2-negative	Epirubicin, cisplatin, infusional 5-FU → paclitaxel + bevacizumab	30	3	33
Rastogi et al⁶⁷	II	HER2-negative	Doxorubicin, cyclophosphamide + bevacizumab → docetaxel + capecitabine + bevacizumab	45	31	9
Ryan et al⁶⁸	II	Triple-negative	Cisplatin + bevacizumab	46	26	15
Makhoul et al⁶⁹	II	Any	Docetaxel, cyclophosphamide + bevacizumab	40	–	33
Greil et al⁶⁵	II	Any	Capecitabine, docetaxel + bevacizumab	18	–	22
Yardley et al⁷⁰	II	HER2-positive	Albumin-bound paclitaxel, carboplatin, trastuzumab + bevacizumab	29	–	65
Smith et al⁷¹	II	HER2-positive	Epirubicin, cyclophosphamide + bevacizumab → docetaxel + bevacizumab + trastuzumab	75	–	53

Rate of complete clinical response.

Rate of complete pathologic response.

Abbreviations: 5-FU = 5-fluorouracil; IHC = immunohistochemistry